Safety and Pharmacokinetics of CBX129801 in Patients With Type 1 Diabetes

Summary

The purpose of this study is to assess safety and tolerability and determine the pharmacokinetics of subcutaneous single and multiple (up to 12) dose administration of CBX129801 (long-acting synthetic C-peptide) in type 1 diabetes patients.

Timeline

Start

2011-04

Primary completion

2012-08

Completion

2012-10

Drugs

Indications